



Date: 18 May 2018

Sydney, Australia

## ASX: NOX

### Noxopharm Limited

ABN 50 608 966 123

#### Registered Office

and

#### Operational Office:

Suite 3 Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

#### Board of Directors

##### Mr Peter Marks

Chairman  
Non-Executive  
Director

##### Dr Graham Kelly

Chief Executive Officer  
Managing Director

##### Dr Ian Dixon

Non-Executive  
Director

## NOXOPHARM 2018 MID-YEAR INVESTOR BRIEFINGS

A reminder to shareholders and the market that a series of mid-year briefings will be held on the following dates;

**Sydney: Thursday June 7<sup>th</sup> at 10.30am – Noxopharm Limited**

**Thursday June 7<sup>th</sup> at 3pm – Nyrada Inc.**

Sofitel Sydney Wentworth Hotel, 61-101 Phillip St, Sydney

**Hobart: Tuesday June 12<sup>th</sup> at 2pm**

Bell Potter Securities, 86 Collins St, Hobart

**Melbourne: Wednesday June 13<sup>th</sup> at 2pm**

Park Hyatt Melbourne, 1 Parliament Square, off Parliament Place, Melbourne

**Gold Coast : Thursday June 14<sup>th</sup> at 2pm**

Surfers Paradise Marriott Resort & Spa, 158 Ferney Ave, Surfers Paradise

**Brisbane : Friday June 15<sup>th</sup> at 10.30am**

Pullman Brisbane Hotel King George Square, cnr Ann & Roma Sts, Brisbane

Noxopharm CEO , Dr Graham Kelly and the Director of Clinical Development and Medical Affairs, Ian Minns will present updates on the Company's clinical programme.

In addition, the Nyrada Chief Scientific Officer, James Bonnar and Chair of the Nyrada Scientific Advisory Board, Professor Gary Housley will provide updates on that Company's scientific progress at the briefings in Sydney and Melbourne.

Enquiries and Registrations: Prue Kelly 0459 022 445, [info@noxopharm.com](mailto:info@noxopharm.com)

**About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product.

**About Nyrada Inc**

Nyrada Inc is a Noxopharm majority-owned subsidiary company formed for the purpose of housing non-oncology drug development intellectual property (IP). Nyrada is a US-registered company based in New York. Its purpose is to house non-oncology IP that is outside Noxopharm's primary focus on oncology drug development and which in the Noxopharm Board's view, represents the best means of creating value for Noxopharm shareholders for non-core IP.

Nyrada has commenced with 3 drug assets across 4 main clinical indications. Each asset is pre-clinical. Nyrada proposes to bring each asset into the clinic.

---

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.